Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On December 12, 2012, Endo Health Solutions Inc. (the Company or Endo) announced that David P. Holveck, 67, the Company's President and Chief Executive Officer and a member of the Company's Board of Directors, will retire in 2013. Mr. Holveck will continue to serve in his present positions until the earlier of his successor being in place or the May 2013 Annual Meeting of Stockholders. Mr. Holveck will also leave the Board of Directors at such time.
Mr. Holveck does not currently serve on any committees on the Company's Board of Directors.
The Board of Directors is conducting a search for the Company's next CEO and will consider both external and internal candidates with the assistance of Korn/Ferry, a leading executive search firm. Item 8.01. Other Events.

Also on December 12, 2012, the Company announced that it now anticipates 2012 adjusted diluted net income per share will be at or below the low end of its previous guidance range of $5.00 to $5.10. Additionally, the Company no longer expects to achieve its previous 2013 guidance for revenues of $3.0 to $3.2 billion and adjusted diluted net income per share of $5.20 to $5.40, and expects to provide updated 2013 guidance in early January.
A copy of the press release announcing these items is furnished as Exhibit 99.1. Adjusted diluted net income per share is a financial measure that is not in conformity with accounting principles generally accepted in the United States and we refer to it as a non-GAAP financial measure. Endo refers to adjusted diluted net income per share in making operating decisions because it believes it provides meaningful supplemental information regarding the Company's operational performance. For instance, Endo believes that this measure facilitates its internal comparisons to its historical operating results and comparisons to competitors' results. The Company believes this measure is useful to investors in allowing for greater transparency related to supplemental information used by Endo in its financial and operational decision-making. In addition, Endo has historically reported similar financial measures to its investors and believes that the inclusion of comparative numbers provides consistency in its financial reporting at this time. Further, Endo believes that adjusted diluted net income per share may be useful to investors as it is aware that certain of its significant stockholders utilize adjusted diluted net income per share to evaluate its financial performance. Finally, adjusted diluted net income per share is used by the Compensation Committee of Endo's Board of Directors in assessing the performance and compensation of substantially all of its employees, including its executive officers. Item 9.01. Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

Not applicable.
(b) Pro Forma Financial Information.

Not applicable.
(c) Shell Company Transactions.

Not applicable.
(d) Exhibits.

Exhibit Number Description
99.1 Press Release

---